SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-21-028340
Filing Date
2021-11-15
Accepted
2021-11-15 08:01:47
Documents
57
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1440145
2 ex31-1.htm EX-31.1 17869
3 ex31-2.htm EX-31.2 16977
4 ex32-1.htm EX-32.1 9596
  Complete submission text file 0001493152-21-028340.txt   4640961

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avte-20210930.xsd EX-101.SCH 34433
6 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avte-20210930_cal.xml EX-101.CAL 40578
7 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avte-20210930_def.xml EX-101.DEF 134058
8 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avte-20210930_lab.xml EX-101.LAB 278341
9 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avte-20210930_pre.xml EX-101.PRE 221812
10 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 523876
Mailing Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116
Business Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40544 | Film No.: 211406453
SIC: 2834 Pharmaceutical Preparations